Two parallel signalling pathways downstream of EGFR, including MEK1/2–ERK1/2 and MEK5–ERK5, phosphorylate and activate the inducible RSK3 protein, eventually leading to the enrichment of activated RSK3 protein in tumour cells to counteract the acute killing effect of JQ1. The gene discussed is MAP2K1; the disease is neoplasm.